

SFB 900 SEMINAR SERIES

ALL GUESTS ARE WELCOME

TITLE

Post-treatment control vs elite control in paediatric and adult HIV infection: What do we know?

SPEAKER

Prof. Philip Goulder
Department of Paediatrics, Medical Sciences Division,
University of Oxford, UK

LOCATION

Lecture Hall B, Building J2
MHH, Carl-Neuberg-Str. 1
Hannover



06.9.
2018

5.00 PM (s.t.)

» Research of Prof. Philip Goulder:

The overarching goal of my research is to identify interventional approaches that will reduce disease in HIV infection, and to explore the particular potential for HIV cure in infected children. My work has sought to define the role of CTL escape in immune control of HIV, the impact of escape mutations on viral replicative capacity, the principal mechanisms of HLA-mediated control of HIV, and the evolutionary aspects of the epidemic. A particular interest of our work is the paediatric HIV epidemic.

Children are highly vulnerable to HIV infection and yet at the same time present unique opportunities to understand mechanisms of HIV disease and the potential for HIV cure. Our interventional studies include the first early ART (anti-retroviral therapy) initiation studies in HIV-infected newborn infants in Africa, and a first-in-man Phase I clinical trial testing peptide immunotherapy to augment T-cell responses. More recently, in July 2015, we have started a 'Baby Cure' study in KwaZulu-Natal, South Africa, in which babies who are HIV-infected in utero are diagnosed and ART initiated within hours of birth.

Prof. Christine Goffinet
Twincore

Tel.: 0511 22002-7198

✉ Christine.Goffinet@twincore.de

Dr. Eugenia Gripp, MHH
Institute of Virology

Tel.: 0511 532-4107

✉ SFB900.Sekretariat@mh-hannover.de